Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | malate dehydrogenase | 0.00518542 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | malate dehydrogenase | 0.00518542 | 1 | 0.5 |
Plasmodium vivax | malate dehydrogenase, putative | 0.00518542 | 1 | 0.5 |
Toxoplasma gondii | malate dehydrogenase MDH | 0.00518542 | 1 | 0.5 |
Echinococcus multilocularis | L lactate dehydrogenase B chain | 0.00518542 | 1 | 1 |
Echinococcus granulosus | lactate dehydrogenase a | 0.00518542 | 1 | 1 |
Plasmodium falciparum | L-lactate dehydrogenase | 0.00518542 | 1 | 0.5 |
Onchocerca volvulus | 0.00472638 | 0.689132 | 0.5 | |
Onchocerca volvulus | Peroxidase homolog | 0.00472638 | 0.689132 | 0.5 |
Toxoplasma gondii | lactate dehydrogenase LDH2 | 0.00518542 | 1 | 0.5 |
Toxoplasma gondii | lactate dehydrogenase LDH1 | 0.00518542 | 1 | 0.5 |
Echinococcus multilocularis | lactate dehydrogenase protein | 0.00518542 | 1 | 1 |
Echinococcus granulosus | lactate dehydrogenase protein | 0.00518542 | 1 | 1 |
Echinococcus granulosus | peroxidasin | 0.00472638 | 0.689132 | 0.689132 |
Onchocerca volvulus | Dual oxidase homolog | 0.00472638 | 0.689132 | 0.5 |
Onchocerca volvulus | Chorion peroxidase homolog | 0.00472638 | 0.689132 | 0.5 |
Leishmania major | malate dehydrogenase, putative | 0.00518542 | 1 | 0.5 |
Echinococcus multilocularis | lactate dehydrogenase a | 0.00518542 | 1 | 1 |
Onchocerca volvulus | 0.00472638 | 0.689132 | 0.5 | |
Echinococcus multilocularis | peroxidasin | 0.00472638 | 0.689132 | 0.689132 |
Brugia malayi | lactate dehydrogenase. | 0.00518542 | 1 | 1 |
Plasmodium vivax | lactate dehydrogenase | 0.00518542 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.00518542 | 1 | 1 |
Onchocerca volvulus | Peroxidase homolog | 0.00472638 | 0.689132 | 0.5 |
Echinococcus multilocularis | lactate dehydrogenase a | 0.00518542 | 1 | 1 |
Onchocerca volvulus | Peroxidasin homolog | 0.00472638 | 0.689132 | 0.5 |
Schistosoma mansoni | L-lactate dehydrogenase | 0.00518542 | 1 | 1 |
Onchocerca volvulus | 0.00472638 | 0.689132 | 0.5 | |
Entamoeba histolytica | malate dehydrogenase, putative | 0.00518542 | 1 | 0.5 |
Echinococcus multilocularis | lactate dehydrogenase a | 0.00518542 | 1 | 1 |
Echinococcus granulosus | L lactate dehydrogenase B chain | 0.00518542 | 1 | 1 |
Onchocerca volvulus | Peroxidasin homolog | 0.00472638 | 0.689132 | 0.5 |
Plasmodium falciparum | malate dehydrogenase | 0.00518542 | 1 | 0.5 |
Echinococcus granulosus | lactate dehydrogenase a | 0.00518542 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence. | ChEMBL. | 22096101 | |
CC50 (functional) | > 64.95 uM | Huh7 cytotoxicity for Pf inhibitors | Novartis-GNF Malaria Box. | No reference |
CC50 | > 64.95 uM | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | ChEMBL. | 18579783 |
EC50 (functional) | = 0.3083 uM | W2 Pf proliferation inhibition | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | = 0.3083 uM | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
EC50 (functional) | = 4.26 uM | PF proliferation inhibition 3D7 | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | = 4.26 uM | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
IFI promiscuity index | = 0 | IFI promiscuity index | Novartis-GNF Malaria Box. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 18579783 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.